SecBot SecBot

XENE

Xenon Pharmaceuticals Inc.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001582313 Biotech & Drug Discovery
$39.26 −1.22 (−3.01%)
Nov 16 4:00 PM ET · prev $40.48
Market cap
$4.0B
Mid cap
Consensus
Buy
92% Buy or better · 25 analysts
Median target
$71.50
+82% · range $46.00–90.00
1 year
−3.3%
from $40.61 · Nov 17
30 days
+11.9%
from $35.08
52-week range
$33.49–70.96
−45% from high · low Oct 16
Avg volume 20D
1.29M
shares / day
Short interest
7.36M
≈7.6% of shares · +0.2%
Days to cover
6.4
at average volume
Insider net
−$10.1M
2 buyers · 6 sellers · since Mar 9
New fund stakes
3
Q2 2026 13F · 1 exit
Filing reports
16
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 0 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 5/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders bought $1.7M at an average $37.36. 6 insiders sold $11.8M. Price is 5% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 37 added (3 new), 20 trimmed or exited. Largest new: Marshall Wace $41.6M, Panagora Asset Management $40.1M.

  • AnalystsBULLISH

    23 of 25 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.194 → −$1.145 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.2% to 7.36M shares. 6.4 days to cover, ≈7.6% of shares.

  • TrendRANGE

    4% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
1
exit
$100.4M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD7,522,482$454.1M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED3,248,219$196.1M
JPMORGAN CHASE & COADD2,617,360$157.4M
WELLINGTON MANAGEMENT GROUP LLPTRIM1,425,492$86.0M
CITADEL ADVISORS LLCTRIM1,401,242$84.6M
GEODE CAPITAL MANAGEMENT, LLCADD1,370,114$82.7M
Pictet Asset Management Holding SAADD1,187,723$71.6M
Nuveen, LLCDOUBLED993,126$59.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

25 analysts
Buy 92% rate it Buy or better
Strong Buy11Buy12Hold2Sell0Strong Sell0
12-month targets · 16 analysts

Price is below the lowest target. Median implies +82%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Sep 18, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Sep 18, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Sep 18, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Sep 18, 2026Deutsche Bank
DOWNGRADE
DOWNGRADEHold
Sep 18, 2026Needham
MAINTAIN
MAINTAINBuy
Sep 18, 2026Baird
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$1.7M
bought · 2 insiders
$11.8M
sold · 6 insiders
+5.1%
vs their $37.36 cost
DateInsiderTypeValue
Oct 15, 2026
Kelly Thomas Patrick
Chief Financial Officer
Oct 15, 2026
EXERCISE7,500 sh
Sep 30, 2026
MORTIMER IAN
PRESIDENT & CEO
Sep 30, 2026
BUY$1.1M
Sep 30, 2026
Kelly Thomas Patrick
Chief Financial Officer
Sep 30, 2026
BUY$559.7K
Sep 1, 2026
Svoronos Dawn
Director
Sep 1, 2026
EXERCISE$41.9K
Aug 28, 2026
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
Aug 28, 2026
SELL$383.1K
Aug 28, 2026
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
Aug 28, 2026
SELL$42.7K
Aug 11, 2026
GANNON STEVEN
Director
Aug 11, 2026
SELL$640.6K
Jun 5, 2026
Cannon Gillian
Director
Jun 5, 2026
SELL$63.2K

Earnings setup

Estimates
−$1.14
EPS estimate, this quarter
+4%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.14-$1.29–-$0.94+0.5%$416.7K
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
7,363,365
shares short
+0.2%
vs prior settlement
6.4
days to cover
≈7.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 9, 2026 Earnings
Xenon Reports Q3 2026 Financial Results and Provides Business Update
VANCOUVER, BC and BOSTON, MA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:
Nov 9, 2026 SEC
Xenon reported Q3 2026 results with a net loss of $110.4M, wider than the $90.9M loss in Q3 2025, driven by higher R&D…
8-K · Impact 5/10
Nov 6, 2026 SEC
T. Rowe Price Investment Management filed an amended Schedule 13G reporting a 10.3% passive stake in Xenon…
SC 13G/A · Impact 2/10
Oct 15, 2026 Insider
Kelly Thomas Patrick acquired via exercise 7,500 shares
Chief Financial Officer
Sep 30, 2026 Insider
MORTIMER IAN bought 30,000 shares
PRESIDENT & CEO @ $37.38 ($1.1M)
Sep 30, 2026 Insider
Kelly Thomas Patrick bought 15,000 shares
Chief Financial Officer @ $37.32 ($559.7K)
Jul 2, 2026 Press
Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement…
Impact 1/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent

SecBot reports

16 filings · 3 press releases · 1 bullish · 3 bearish · 1 mixed · 11 neutral
All XENE filing & press-release reports (19)